Published in Medical Letter on the CDC and FDA, March 28th, 2004
The FDA has completed its review of Three Rivers' Abbreviated New Drug Application (ANDA) for ribavirin and has concluded that the application is approvable. Final approval is subject only to resolution of certain regulatory issues involving final product labeling.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.